Dostarlimab eliminates need for cancer surgery, chemo

A new immunotherapy drug, dostarlimab, has shown remarkable success in treating certain cancers, eliminating the need for surgery, chemotherapy, and radiation in many patients. In a clinical trial, 84 out of 103 patients with specific genetic mutations saw their tumors disappear after receiving dostarlimab. Notably, all 49 rectal cancer patients achieved complete remission. This groundbreaking treatment, targeting cancers with MMRd mutations, offers a less invasive approach and could revolutionize cancer care, potentially avoiding harsh side effects and organ removal.